Eslicarbazepine acetate for the treatment of partial epilepsy

References

• Iyer A, Marson A. Pharmacotherapy of focal epilepsy. Expert Opin Pharmacother. 2014 Aug;15(11):1543–1551.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Practical use of newer antiepileptic drugs as adjunctive therapy in focal epilepsy. CNS Drugs. 2015 Oct 27;29:893–904.
   PubMed Web of Science ®Google Scholar
• Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935–946.
   PubMed Web of Science ®Google Scholar
• Falcao A, Pinto R, Nunes T, et al. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. Epilepsy Res. 2013 Sep;106(1–2):244–249.
   PubMed Web of Science ®Google Scholar
• Rocha JF, Vaz-da-Silva M, Almeida L, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther. 2009 Apr;47(4):255–261.
   PubMed Web of Science ®Google Scholar
• Vaz da Silva M, Costa R, Soares E, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol. 2009 Aug;23(4):509–514.
   PubMed Web of Science ®Google Scholar
• Vaz-da-Silva M, Almeida L, Falcao A, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther. 2010 Jan;32(1):179–192.
   PubMed Web of Science ®Google Scholar
• Falcao A, Vaz-da-Silva M, Gama H, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res. 2013 Aug;105(3):368–376.
   PubMed Web of Science ®Google Scholar
• Nunes T, Rocha JF, Falcao A, et al. Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia. 2013 Jan;54(1):108–116.
   PubMed Web of Science ®Google Scholar
• Banach M, Borowicz KK, Czuczwar SJ. Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):639–648.
   PubMed Web of Science ®Google Scholar
• Bonifacio MJ, Sheridan RD, Parada A, et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia. 2001 May;42(5):600–608.
   PubMed Web of Science ®Google Scholar
• Hebeisen S, Pires N, Loureiro AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology. 2015 Feb;89:122–135.
   PubMed Web of Science ®Google Scholar
• Sierra-Paredes G, Nunez-Rodriguez A, Vazquez-Lopez A, et al. Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats. Epilepsy Res. 2006 Dec;72(2–3):140–146.
   PubMed Web of Science ®Google Scholar
• Shorvon SD, Perucca E, Engel J. Jr. The treatment of epilepsy. 3rd ed. Oxford: Wiley-Blackwell; 2009.
   Google Scholar
• Potschka H, Soerensen J, Pekcec A, et al. Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. Epilepsy Res. 2014 Feb;108(2):212–222.
   PubMed Web of Science ®Google Scholar
• Perucca E, Elger C, Halasz P, et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res. 2011 Sep;96(1–2):132–139.
   PubMed Web of Science ®Google Scholar
• Almeida L, Potgieter JH, Maia J, et al. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008 Mar;64(3):267–273.
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol. 2004 Aug;44(8):906–918.
   PubMed Web of Science ®Google Scholar
• Almeida L, Falcao A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005 Sep;45(9):1062–1066.
   PubMed Web of Science ®Google Scholar
• Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007 Mar;48(3):497–504.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gabbai AA, Hufnagel A, et al. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy. Epilepsy Res. 2010 May;89(2–3):278–285.
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009 Mar; 50(3):454–463.
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, et al. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand. 2009 Nov; 120(5):281–287.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015 Feb;56(2):244–253.
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Elger C, Ben-Menachem E, et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia. 2013 Jan;54(1):98–107.
   PubMed Web of Science ®Google Scholar
• Hufnagel A, Ben-Menachem E, Gabbai AA, et al. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res. 2013 Feb;103(2–3):262–269.
   PubMed Web of Science ®Google Scholar
• Halasz P, Cramer JA, Hodoba D, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia. 2010 Oct;51(10):1963–1969.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Harvey J, Grinnell T, et al. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Epilepsia. 2015 Apr;56(4):546–555.
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Pazdera L, Bhatia P, et al. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurol. 2015;15:46.
   PubMed Web of Science ®Google Scholar
• Sperling MR, French J, Jacobson MP, et al. Conversion to eslicarbazepine acetate monotherapy: a pooled analysis of 2 phase III studies. Neurology. 2016 Feb 24;86:1095–1102.
   Web of Science ®Google Scholar
• Serrano-Castro PJ, Payan-Ortiz M, Cimadevilla JM, et al. Eslicarbazepine acetate in clinical practice. Efficacy safety results. Rev Neurol. 2013 Mar 16;56(6):309–314.
   PubMed Web of Science ®Google Scholar
• Massot A, Vivanco R, Principe A, et al. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results. Neurologia. 2014 Mar;29(2):94–101.
   PubMed Web of Science ®Google Scholar
• Correia FD, Freitas J, Magalhaes R, et al. Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study. Epilepsy Res. 2014 Oct;108(8):1399–1405.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Serratosa JM, Guillamon E, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res. 2014 Sep;108(7):1243–1252.
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007 Mar 24;369(9566):1000–1015.
   PubMed Web of Science ®Google Scholar